{"id":"W2292681792","doi":"10.1002/clc.22518","title":"Comparison of <scp>PCSK9</scp> Inhibitor Evolocumab vs Ezetimibe in Statin‐Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti‐<scp>PCSK9</scp> Antibody in Statin‐Intolerant Subjects 3 (<scp>GAUSS</scp>‐3) Trial","year":2016,"lang":"en","type":"article","venue":"Clinical Cardiology","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia","funders":"Kowa Company; Medicines Company; Cleveland Clinic; Sanofi; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Evolocumab; PCSK9; Statin; Ezetimibe; Kexin; Pharmacology; Alirocumab; Proprotein convertase; Internal medicine; Cholesterol; Apolipoprotein B; LDL receptor; Lipoprotein","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.009235246,0.0009183698,0.005143292,0.0005228809,0.0001491888,0.00003460217,0.0008048013,0.001176202,0.00001354411],"category_scores_gemma":[0.01123174,0.0005995411,0.001569464,0.0008633446,0.001190589,0.0002848932,0.0005311323,0.001801752,0.00003067134],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003842749,"about_ca_system_score_gemma":0.001153778,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005589814,"about_ca_topic_score_gemma":0.0001893014,"domain_scores_codex":[0.9831587,0.006564392,0.005027607,0.001749567,0.001722411,0.001777291],"domain_scores_gemma":[0.9883193,0.006375136,0.001597175,0.002288217,0.0007755466,0.0006446482],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.004352957,0.003298566,0.9698566,0.0005457001,0.0008336629,0.0001843247,0.002427031,0.0004147604,0.00450959,0.00006346793,0.001415518,0.0120978],"study_design_scores_gemma":[0.06902236,0.01178267,0.9042972,0.001140179,0.0005259434,0.00003180562,0.002309131,0.000597347,0.005520778,0.0001676244,0.004428321,0.0001766539],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9866804,0.001441204,0.003476704,0.0001824094,0.002360872,0.005247613,0.0002232991,0.00007779821,0.0003096454],"genre_scores_gemma":[0.9957835,0.0005270765,0.0012394,0.0006025996,0.001171852,0.0003431372,0.0001210376,0.0001368053,0.00007460337],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06555943,"threshold_uncertainty_score":0.9996456,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0503216242098047,"score_gpt":0.3704754097644569,"score_spread":0.3201537855546522,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}